{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T13:45:00Z","timestamp":1790603100586,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.berh.2020.101489","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T03:38:41Z","timestamp":1583725121000},"page":"101489","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Scleroderma mimics \u2013 Clinical features and management"],"prefix":"10.1016","volume":"34","author":[{"given":"Catherine H.","family":"Orteu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Voon H.","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Denton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.berh.2020.101489_bib1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jaad.2010.05.045","article-title":"Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis","volume":"64","author":"Fett","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.berh.2020.101489_bib2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jaad.2010.05.046","article-title":"Update on morphea: part II. Outcome measures and treatment","volume":"64","author":"Fett","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.berh.2020.101489_bib3","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3899\/jrheum.130029","article-title":"Clinical features of patients with morphea and the pansclerotic subtype: a cross-sectional study from the morphea in adults and children cohort","volume":"41","author":"Kim","year":"2014","journal-title":"J\u00a0Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2020.101489_bib4","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/rheumatology\/kei251","article-title":"Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study","volume":"45","author":"Zulian","year":"2006","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.berh.2020.101489_bib5","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/archdermatol.2009.79","article-title":"Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases","volume":"145","author":"Leitenberger","year":"2009","journal-title":"Arch Dermatol"},{"issue":"10103","key":"10.1016\/j.berh.2020.101489_bib6","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.berh.2020.101489_bib7","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.berh.2020.101489_bib8","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/acr.22451","article-title":"The 2013 ACR\/EULAR classification criteria for systemic sclerosis out-perform the 1980 criteria. Data from the Canadian scleroderma Research group","volume":"67","author":"Alhajeri","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.berh.2020.101489_bib9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jaad.2017.06.148","article-title":"Clinicopathologic and immunophenotypic features of eosinophilic fasciitis and morphea profunda: a comparative study of 27 cases","volume":"78","author":"Onajin","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.berh.2020.101489_bib10","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s40257-017-0269-x","article-title":"Morphea and eosinophilic fasciitis: an update","volume":"18","author":"Mertens","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.berh.2020.101489_bib11","first-page":"46","article-title":"Diffuse fasciitis with hypergammaglobulinaemia and eosinophilia:a new syndrome?","volume":"1","author":"LE","year":"1974","journal-title":"J\u00a0Rheumatol Suppl"},{"issue":"4","key":"10.1016\/j.berh.2020.101489_bib12","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.clindermatol.2018.04.006","article-title":"Eosinophilic fasciitis: current concepts","volume":"36","author":"Fett","year":"2018","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.berh.2020.101489_bib13","doi-asserted-by":"crossref","first-page":"212529","DOI":"10.7573\/dic.212529","article-title":"Eosinophilic fasciitis: a case series with an emphasis on therapy and induction of remission","volume":"7","author":"Tull","year":"2018","journal-title":"Drugs Context"},{"issue":"5","key":"10.1016\/j.berh.2020.101489_bib14","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1046\/j.1468-3083.2003.00780.x","article-title":"Chronic graft versus host disease and skin","volume":"17","author":"Fimiani","year":"2003","journal-title":"J\u00a0Eur Acad Dermatol Venereol : JEADV"},{"issue":"1","key":"10.1016\/j.berh.2020.101489_bib15","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1177\/039463201002300139","article-title":"Clinical, serologic and instrumental data of ten patients affected by sclerodermatous chronic graft versus host disease: similarities and differences in respect to systemic sclerosis","volume":"23","author":"Barausse","year":"2010","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"12","key":"10.1016\/j.berh.2020.101489_bib16","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1111\/jdv.13272","article-title":"Scleredema. A multicentre study of characteristics, comorbidities, course and therapy in 44 patients","volume":"29","author":"Rongioletti","year":"2015","journal-title":"J\u00a0Eur Acad Dermatol Venereol : JEADV"},{"issue":"10","key":"10.1016\/j.berh.2020.101489_bib17","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/jdv.14466","article-title":"European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: scleromyxedema, scleredema and nephrogenic systemic fibrosis","volume":"31","author":"Knobler","year":"2017","journal-title":"J\u00a0Eur Acad Dermatol Venereol : JEADV"},{"issue":"1","key":"10.1016\/j.berh.2020.101489_bib18","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaad.2013.01.007","article-title":"Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients","volume":"69","author":"Rongioletti","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.berh.2020.101489_bib19","doi-asserted-by":"crossref","first-page":"408","DOI":"10.2340\/00015555-1299","article-title":"Scleromyxoedema: clinical follow-up after successful treatment with high-dose immunoglobulins reveals different long-term outcomes","volume":"92","author":"Bidier","year":"2012","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"10.1016\/j.berh.2020.101489_bib20","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/j.1365-2133.2007.08169.x","article-title":"Arndt-Gottron scleromyxoedema: successful therapy with intravenous immunoglobulins","volume":"157","author":"Gholam","year":"2007","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.berh.2020.101489_bib21","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.trsl.2014.06.002","article-title":"Allogeneic stem cell transplantation for the treatment of refractory scleromyxedema","volume":"165","author":"Shayegi","year":"2015","journal-title":"Transl Res : J Lab Clin Med"},{"issue":"5","key":"10.1016\/j.berh.2020.101489_bib22","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1600-0609.2012.01772.x","article-title":"The combination of bortezomib and dexamethasone is an efficient therapy for relapsed\/refractory scleromyxedema: a rare disease with new clinical insights","volume":"88","author":"Canueto","year":"2012","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.berh.2020.101489_bib23","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejrad.2008.01.016","article-title":"Clinical and histological findings in nephrogenic systemic fibrosis","volume":"66","author":"Cowper","year":"2008","journal-title":"Eur J Radiol"},{"issue":"1","key":"10.1016\/j.berh.2020.101489_bib24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jacr.2007.08.013","article-title":"Nephrogenic systemic fibrosis: an overview","volume":"5","author":"Cowper","year":"2008","journal-title":"J\u00a0Am Coll Radiol"},{"issue":"5","key":"10.1016\/j.berh.2020.101489_bib25","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1002\/jmri.24664","article-title":"Diagnosing nephrogenic systemic fibrosis in the post-FDA restriction era","volume":"41","author":"Thomson","year":"2015","journal-title":"J\u00a0Magn Reson Imag : JMRI"},{"issue":"6","key":"10.1016\/j.berh.2020.101489_bib26","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.jaad.2010.08.041","article-title":"Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations","volume":"65","author":"Girardi","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.berh.2020.101489_bib27","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.semnephrol.2011.05.010","article-title":"Gadolinium-induced nephrogenic systemic fibrosis","volume":"31","author":"Hellman","year":"2011","journal-title":"Semin Nephrol"},{"issue":"2","key":"10.1016\/j.berh.2020.101489_bib28","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1148\/radiol.2502080498","article-title":"Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment-report of 33 cases","volume":"250","author":"Perez-Rodriguez","year":"2009","journal-title":"Radiology"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694220300061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694220300061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:20:29Z","timestamp":1761499229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694220300061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1521694220300061"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2020.101489","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Scleroderma mimics \u2013 Clinical features and management","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2020.101489","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101489"}}